ArticleInterdisciplinary sciences, computational life sciences2026
GSF-DTA: An Innovative Graph-Sequence Fusion Framework for Drug-Target Affinity Prediction.
Article in Interdisciplinary sciences, computational life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-target cell membrane chromatography intelligent screening strategy and its application in drug discovery.Journal of pharmaceutical analysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Drug development is a lengthy and intricate process, where predicting drug-target affinity (DTA) is a vital step. Although traditional experimental techniques yield accurate and reliable results, their high cost and limited throughput render them impractical for large-scale applications. In contrast, computational approaches offer notable advantages in terms of scalability and operational efficiency. However, most existing models focus solely on either sequence information or molecular graph structure, limiting their capacity to capture the multifaceted nature of drug-target interactions. In the present work, we propose GSF-DTA, a novel graph-sequence fusion framework for DTA prediction. GSF-DTA integrates graph-based structural features and sequence-derived semantic representations to capture the interplay between drugs and targets. Quantitative evaluations demonstrate that GSF-DTA achieves superior predictive accuracy and exhibits strong generalization capabilities on the large-scale BindingDB dataset. Notably, GSF-DTA demonstrates robust performance in cold-start scenarios, enabling effective prediction for previously unseen drugs or targets. Extensive ablation studies and interpretability analyses further validate the effectiveness and transparency of our approach. Overall, GSF-DTA provides a promising and generalizable strategy for improving DTA prediction accuracy, contributing to the acceleration of drug design and discovery.
Indexed as
Identifiers
41233668What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.